A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Biogen Inc. stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 2,132 shares of BIIB stock, worth $312,274. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,132
Previous 2,229 4.35%
Holding current value
$312,274
Previous $516,000 19.96%
% of portfolio
0.02%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$189.07 - $236.8 $18,339 - $22,969
-97 Reduced 4.35%
2,132 $413,000
Q2 2024

Aug 12, 2024

BUY
$190.52 - $236.72 $24,386 - $30,300
128 Added 6.09%
2,229 $516,000
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $91,168 - $115,115
430 Added 25.73%
2,101 $453,000
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $103,504 - $124,592
-465 Reduced 21.77%
1,671 $432,000
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $53,193 - $60,036
210 Added 10.9%
2,136 $548,000
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $16,239 - $18,765
-59 Reduced 2.97%
1,926 $549,000
Q1 2023

May 09, 2023

SELL
$256.56 - $292.34 $2,565 - $2,923
-10 Reduced 0.5%
1,985 $552,000
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $97,189 - $118,087
-385 Reduced 16.18%
1,995 $552,000
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $42,831 - $59,061
-220 Reduced 8.46%
2,380 $635,000
Q2 2022

Aug 16, 2022

BUY
$187.54 - $223.02 $22,504 - $26,762
120 Added 4.84%
2,600 $530,000
Q1 2022

May 17, 2022

SELL
$193.77 - $244.14 $87,002 - $109,618
-449 Reduced 15.33%
2,480 $522,000
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $23,735 - $30,503
106 Added 3.75%
2,929 $703,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $28,299 - $36,905
-100 Reduced 3.42%
2,823 $799,000
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $274,540 - $439,592
-1,060 Reduced 26.61%
2,923 $1.01 Million
Q1 2021

May 14, 2021

BUY
$242.95 - $284.63 $150,871 - $176,755
621 Added 18.47%
3,983 $1.11 Million
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $128,525 - $193,462
544 Added 19.3%
3,362 $823,000
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $373,325 - $431,051
-1,410 Reduced 33.35%
2,818 $799,000
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $300,045 - $397,358
1,160 Added 37.81%
4,228 $1.13 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $454,356 - $576,357
-1,690 Reduced 35.52%
3,068 $971,000
Q4 2019

Feb 13, 2020

SELL
$220.06 - $304.07 $600,763 - $830,111
-2,730 Reduced 36.46%
4,758 $1.41 Million
Q3 2019

Nov 13, 2019

SELL
$217.44 - $243.88 $9,132 - $10,242
-42 Reduced 0.56%
7,488 $1.74 Million
Q2 2019

Aug 13, 2019

BUY
$219.29 - $241.72 $120,170 - $132,462
548 Added 7.85%
7,530 $1.76 Million
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $25,138 - $39,319
116 Added 1.69%
6,982 $1.65 Million
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $125,882 - $159,443
-452 Reduced 6.18%
6,866 $2.07 Million
Q2 2018

Aug 13, 2018

BUY
$257.52 - $306.91 $100,432 - $119,694
390 Added 5.63%
7,318 $2.12 Million
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $46,823 - $66,223
-180 Reduced 2.53%
6,928 $1.9 Million
Q3 2017

Nov 08, 2017

BUY
$281.15 - $329.69 $2 Million - $2.34 Million
7,108
7,108 $2.23 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Meiji Yasuda Asset Management CO Ltd. Portfolio

Follow Meiji Yasuda Asset Management CO Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.